0000000000327744

AUTHOR

Elena Collovà

showing 5 related works from this author

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

2015

Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC). Materials and methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: <1 year, between 1 and 5 years and >5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance. R…

OncologyAdultMalemedicine.medical_specialtyCancer ResearchPrognosimedicine.medical_treatmentBone NeoplasmsBone NeoplasmPrognostic factorsMetastasisRenal cell carcinomaRetrospective StudieBone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis; Cancer Research; OncologyInternal medicineBone metastasis Prognostic factors Renal cell carcinoma Time to distant metastasisCarcinomaMedicineHumansLymph nodeCarcinoma Renal CellSurvival analysisAgedRetrospective StudiesBone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis; Adult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Cancer Research; OncologyAged 80 and overPrognostic factorTime to distant metastasibusiness.industryResearchTime to distant metastasisBone metastasisKidney NeoplasmBone metastasisMiddle Agedmedicine.diseasePrognosisSurvival AnalysisNephrectomyRenal cell carcinomaKidney Neoplasmsmedicine.anatomical_structureOncologyConcomitantBone metastasiFemaleSurvival AnalysibusinessHumanJournal of Experimental & Clinical Cancer Research
researchProduct

Anticancer oral therapy: Emerging related issues

2010

The use of oral anticancer drugs has shown a steady increase. Most patients prefer anticancer oral therapy to intravenous treatment primarily for the convenience of a home-based therapy, although they require that the efficacy of oral therapy must be equivalent and toxicity not superior than those expected with the intravenous treatment. A better patient compliance, drug tolerability, convenience and possible better efficacy for oral therapy as compared to intravenous emerge as the major reasons to use oral anticancer agents among oncologists. Inter- and intra-individual pharmacokinetic variations in the bioavailability of oral anticancer drugs may be more relevant than for intravenous agen…

MaleCost-Benefit AnalysisPsychological interventionAdministration OralPharmacologyAntineoplastic AgentPharmacogenomicNeoplasmsMedicineDrug InteractionsInfusions IntravenouInfusions IntravenousCancermedia_commonOraltherapyGeneral MedicineTreatment OutcomeDrug InteractionOncologyTolerabilityPatient SatisfactionFemaleComplianceDrug-drug interactionHumanQuality of lifeDrugmedicine.medical_specialtyCostmedia_common.quotation_subjectPharmacokineticAntineoplastic AgentsDrug Administration ScheduleFollow-Up StudiePersistenceQuality of life (healthcare)Patient satisfactionPharmacokineticsHumansRadiology Nuclear Medicine and imagingCost-Benefit AnalysiAdverse effectIntensive care medicineDose-Response Relationship Drugbusiness.industryAdherencePharmacogenomicsNeoplasmPatient CompliancebusinessFollow-Up StudiesForecastingCancer Treatment Reviews
researchProduct

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.

2015

Aim To assess patient perception toward oral chemotherapy for solid tumors, the Italian Association of Medical Oncology performed a large multi-institutional national survey. Methods A 17-item anonymous questionnaire including 7 general and 10 investigational questions with free-text, single-choice, or multiple-choice answers was administered. Analysis of response distribution according to predefined factors was described by summary measures and conducted by χ2 test and other nonparametric tests. Results From January to June 2010, 581 patients completed the questionnaire; data of 404 patients constituted the final study sample. Three groups could be distinguished according to treatment: IV …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyOral chemotherapyAdministration OralWork commitment03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImpact on family030212 general & internal medicineInfusions IntravenousOral therapyAgedbusiness.industryIntravenous chemotherapyGeneral MedicineMiddle AgedPatient perceptionsOncologyItaly030220 oncology & carcinogenesisQuality of LifeCombined therapyFemalebusinessTumori
researchProduct

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

2015

AbstractWe conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median su…

OncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentECOG Performance StatusBone NeoplasmsYoung AdultInternal medicineCarcinomamedicine80 and overHumansYoung adultLung cancerNon-Small-Cell LungAgedLungMultidisciplinarybusiness.industryAdult Aged Aged 80 and over Bone Neoplasms Carcinoma Non-Small-Cell Lung Female Humans Lung Neoplasms Male Middle Aged Young Adult Disease Progression MultidisciplinaryCarcinomaBone metastasisMiddle Agedmedicine.diseaseRadiation therapymedicine.anatomical_structureConcomitantDisease ProgressionFemaleAdult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Young Adult; Disease Progressionbusiness
researchProduct

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

2016

We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival a…

AdultAged 80 and overMaleLung NeoplasmsBone NeoplasmsMiddle AgedCorrigendaArticleYoung AdultCarcinoma Non-Small-Cell LungDisease ProgressionHumansFemaleAgedScientific reports
researchProduct